前列腺癌雄激素剥夺治疗与新发痴呆及阿尔茨海默病风险的系统评价与荟萃分析
该系统评价与荟萃分析纳入14项研究,评估前列腺癌患者接受雄激素剥夺治疗(ADT)后痴呆和/或阿尔茨海默病的发生风险。结果显示,接受ADT的患者新发痴呆(HR 1.21,95%CI 1.11-1.33)和阿尔茨海默病(HR 1.16,95%CI 1.09-1.24)风险均升高;ADT超过12个月时全因痴呆风险更高(HR 1.36,95%CI 1.07-1.72)。
要点
- ADT与前列腺癌患者新发痴呆和阿尔茨海默病风险升高相关。
- ADT暴露超过12个月时全因痴呆风险显著增加(HR 1.36)。
- ADT暴露不足12个月时痴呆风险差异无统计学意义。
核心结论
- 前列腺癌患者接受ADT较未接受ADT者新发痴呆和/或阿尔茨海默病风险升高。
- ADT疗程超过12个月时全因痴呆风险升高更明显。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Web of Science数据库(2020年1月1日至3日)。
- 最终纳入14项研究,其中9项报告全因痴呆,8项报告阿尔茨海默病,5项按ADT疗程评估结局。
主要发现
- 接受ADT的前列腺癌患者全因痴呆风险升高(HR 1.21,95%CI 1.11-1.33)。
- 接受ADT的前列腺癌患者阿尔茨海默病风险升高(HR 1.16,95%CI 1.09-1.24)。
- ADT超过12个月者全因痴呆风险升高(HR 1.36,95%CI 1.07-1.72)。
- ADT不足12个月者全因痴呆风险差异无统计学意义(HR 1.06,95%CI 0.77-1.28)。
- ADT疗程与阿尔茨海默病风险无显著关联(≤12个月HR 1.21,95%CI 0.97-1.51;>12个月HR 1.39,95%CI 0.69-2.79)。
临床怎么用
- 对计划接受ADT的前列腺癌患者,应评估痴呆相关基线风险并加强认知监测。
- 对于需长期ADT(超过12个月)的患者,应更关注痴呆风险并定期进行认知功能筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Androgen deprivation therapy is a standard therapy for some patients with localized and almost all patients with metastatic prostate cancer. Although several clinical cohort studies have identified an impact of androgen deprivation therapy on cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer disease. Consequently there is still a lack of systematic review and meta-analysis regarding the impact of this risk including more recent studies. MATERIALS AND METHODS: We conducted a systematic review and meta-analysis of the literature assessing the differential incidence of dementia and/or Alzheimer disease as outcomes in patients with prostate cancer who did vs did not receive androgen deprivation therapy. We queried PubMed® and Web of Science™ databases from January 1 to 3, 2020. We used random or fixed effects meta-analytic models in the presence or absence of heterogeneity per the I2 statistic. We performed 6 meta-analyses for all cause dementia, Alzheimer disease and all cause dementia or Alzheimer disease according to the duration of androgen deprivation therapy (up to 12 or more than 12 months). RESULTS: A total of 14 studies were selected after considering inclusion and exclusion criteria. Nine of them reported all cause dementia (ie all types of dementia including Alzheimer disease), with 8 reporting Alzheimer disease. Five studies assessed these outcomes according to the duration of androgen deprivation therapy. The risk of new onset dementia (all cause) and Alzheimer disease was higher in patients with prostate cancer who received androgen deprivation therapy compared to those who did not (HR 1.21, 95% CI 1.11-1.33 and HR 1.16, 95% CI 1.09-1.24). The risk of dementia (all cause) was higher in patients with prostate cancer who received androgen deprivation therapy for more than 12 months (HR 1.36, 95% CI 1.07-1.72); however, for those who had less than 12 months of androgen deprivation therapy exposure the difference was not statistically significant 1.06 (95% CI 0.77-1.28). There was no association between the androgen deprivation therapy duration and the risk of Alzheimer disease (HR 1.21, 95% CI 0.97-1.51 for exposure up to 12 months and HR 1.39, 95% CI 0.69-2.79 for exposure greater than 12 months). CONCLUSIONS: Men who receive androgen deprivation therapy for prostate cancer have an increased risk of dementia and/or Alzheimer disease compared to men who do not receive androgen deprivation therapy; this was more pronounced when androgen deprivation therapy was given longer than 12 months.
引用
- Sari Motlagh R, Quhal F, Mori K, et al. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2020. PMID: 32856962. doi:10.1097/JU.0000000000001341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。